<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02113917</url>
  </required_header>
  <id_info>
    <org_study_id>NI10015</org_study_id>
    <secondary_id>AOM 10219</secondary_id>
    <nct_id>NCT02113917</nct_id>
  </id_info>
  <brief_title>Children and Adult Hemophagocytic Syndrome (HLHa)</brief_title>
  <acronym>HLH-genes</acronym>
  <official_title>The Formation of a Cohort of HLHa Patients in Order to Study Their Physiopathological Characteristics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Laboratory of normal and pathological development Immune System - IFR 94 U768</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Reference Centre for Hereditary Immunodeficiency: CEREDIH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Different study of HLHa patients :&#xD;
&#xD;
        -  Diagnosis criteria, because criteria are based on pediatric genetic studies.&#xD;
&#xD;
        -  Physiopathological studies: genetic studies have demonstrated the role of CD8+ cells, in&#xD;
           particular because they have a genetic defect affecting their cytotoxic functions in HLH&#xD;
           pediatric. the aim is to establish if the same defect is found in both some or in all of&#xD;
           HLHa patients. If this is the case, to then establish whether hypomorphic genetic&#xD;
           mutations are responsible.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Formation of a prospective and retrospective infant, adolescent and adult HLH patients&#xD;
      cohort.&#xD;
&#xD;
      Collection of clinical and biological, therapeutics, informations, in a register, The&#xD;
      collection of information is:&#xD;
&#xD;
        -  To identify clinical and biological criteria specific to HLHa&#xD;
&#xD;
        -  Classify patients into homogeneous groups, based on clinical biological scalability in&#xD;
           particular, with regards to their response to treatment&#xD;
&#xD;
        -  Identify and analyze the behavioral therapy Creation of a bank of biological samples for&#xD;
           use in the study of the pathophysiology of HLHa.&#xD;
&#xD;
      Background:&#xD;
&#xD;
      The hemophagocytic syndrome in infant, adolescent and adults (HLH) is a serious and often&#xD;
      lethal condition. The study of literature series HLHa shows that these syndromes frequently&#xD;
      develop in immunocompromised patients (renal transplant, HIV, collagen in Processing&#xD;
      immunosuppressants) in the course of a viral infection. HLH syndrome has also been described&#xD;
      as a clinical form of lymphoma or connective disease (lupus). These clinical forms are rare,&#xD;
      severe and recurrent suggesting the possibility that immune deficiency could be involved. The&#xD;
      study of pediatric forms has definitely established a link between HLH syndrome and the&#xD;
      presence of immune deficiency by identifying the nature of the latter. Four genetically&#xD;
      determined diseases are manifested by HLH syndrome. These conditions are Family&#xD;
      lymphohistiocytosis (LHF) syndrome, Chediak-Higashi CHS syndrome, Griscelli (GS) type 2&#xD;
      syndromes and X-linked lymphoproliferative (XLP 1 and 2). The mutated genes are respectively&#xD;
      perforin Unc 13.4 and syntaxin in the LHF2, 3, 4 (10q locus genetic for LHF 1), CHS1/LYST&#xD;
      (Lysosomal Trafficking regulator) in the CHS, in the Rab27a GS type 2, and XIAP and SH2D1A in&#xD;
      the XLP. It is now well established that proteins encoded by these genes are necessary for&#xD;
      the cytotoxic function of CD8 + and in the absence of these proteins is the cytotoxocity CD8&#xD;
      + deficient. Also, closed clinical and biological characteristics shared by pediatric genetic&#xD;
      and adult forms suggest the existence of immune defects responsible for some or all HLH adult&#xD;
      patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>biologicals criteria</measure>
    <time_frame>T0 (before traitment</time_frame>
    <description>measure of : cytokines expression (mmol/L) Hemoglobin (g/dl) number of Platelets (number/L) number of Neutrophils (number/L) number of triglycerides (mmol/L) number of fibrinogen (g/L) number of Ferritin (microg/L)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>name of treatment</measure>
    <time_frame>T2 (T2 is the first day of treatment)</time_frame>
    <description>administrated treatments</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinicals criteria</measure>
    <time_frame>T0</time_frame>
    <description>clinicals description of patients : Fever, Splenomegaly and adenopathy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>biologicals criteria</measure>
    <time_frame>T1 (T1 is the first day of HLH syndrome)</time_frame>
    <description>measure of : cytokines expression Hemoglobin level number of Platelets number of Neutrophils number of triglycerides&gt; number of fibrinogen number of Ferritin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>biologicals criteria</measure>
    <time_frame>T2 (T2 is the first day of treatment)</time_frame>
    <description>measure of : cytokines expression Hemoglobin level number of Platelets number of Neutrophils number of triglycerides&gt; number of fibrinogen number of Ferritin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>biologicals criteria</measure>
    <time_frame>T4 (6 /12 months after the resolution of HLH)</time_frame>
    <description>measure of : cytokines expression Hemoglobin level number of Platelets number of Neutrophils number of triglycerides&gt; number of fibrinogen number of Ferritin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinicals criteria</measure>
    <time_frame>T1(T1 is the first day of HLH syndrome)</time_frame>
    <description>clinicals description of patients : Fever, Splenomegaly and adenopathy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinicals criteria</measure>
    <time_frame>T2 (T2 is the first day of treatment)</time_frame>
    <description>clinicals description of patients : Fever, Splenomegaly and adenopathy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinicals criteria</measure>
    <time_frame>T4 6 /12 months after the resolution of HLH)</time_frame>
    <description>clinicals description of patients : Fever, Splenomegaly and adenopathy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>name of treatment</measure>
    <time_frame>T4(6/12 month after resolution of HLH)</time_frame>
    <description>administrated treatments</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">204</enrollment>
  <condition>Hemophagocytic Syndrome</condition>
  <arm_group>
    <arm_group_label>hemophagocytic syndrome</arm_group_label>
    <description>patient with hemophagocytic syndrome</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Identification of biological markers</intervention_name>
    <arm_group_label>hemophagocytic syndrome</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood and serum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Infant, Adolescent and adult patients who have a HLH syndrome regardless of etiology,&#xD;
        hospitalized in Internal Medicine, Critical Care, Hematology, Rheumatology Neurology or&#xD;
        Organ Transplantation&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Major criteria:&#xD;
&#xD;
          -  hemophagocytosis found in a specimen histology.&#xD;
&#xD;
          -  Fever&#xD;
&#xD;
          -  Splenomegaly&#xD;
&#xD;
        Minor criteria:&#xD;
&#xD;
          -  adenopathy&#xD;
&#xD;
          -  cytopenia&gt; 2 cell lines Hemoglobin &lt;9 g / dl (less than 4 weeks and&gt; 12 g / dl)&#xD;
             Platelets &lt;100 000 x 10 / l Neutrophils &lt;1 10 / l&#xD;
&#xD;
          -  hypertriglyceridaemia and / or hypofibrinogenaemia Elevated triglycerides&gt; 3 mmol / l&#xD;
             Fibrinogen &lt;1.5 g / l&#xD;
&#xD;
          -  Ferritin&gt; 500 microg / L&#xD;
&#xD;
        These criteria will be those used for the diagnosis of HLH in adults:&#xD;
&#xD;
        One major criterion and two minor (including hyper ferritin or hypertriglyceridemia) 3&#xD;
        minor criteria (including hyper ferritin or hypertriglyceridemia)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  A person under guardianship&#xD;
&#xD;
          -  Patients under the age of 2 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier Hermine, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Necker Enfants Malades, Assistance Publique des Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Unit</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <study_first_submitted>May 24, 2013</study_first_submitted>
  <study_first_submitted_qc>April 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2014</study_first_posted>
  <last_update_submitted>August 25, 2016</last_update_submitted>
  <last_update_submitted_qc>August 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>infant, adolescent and adult Hemophagocytic Syndrome</keyword>
  <keyword>Hemophagocytic lymphohistiocytosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphohistiocytosis, Hemophagocytic</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

